secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2022-04-13T23:59:59+00:00
Accession:  0001683168-22-002580
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte raises CEO and CFO salaries; Nasdaq confirms listing compliance
--------------------------------------------------------------------------

- CEO Kenneth Waggoner salary increased from $375K to $520K, retroactive to Jan 1, 2022.
- CFO Carlos Trujillo salary increased from $275K to $380K, retroactive to Jan 1, 2022.
- Nasdaq Staff determined company meets independent director requirement after appointing Dr. Matthias Löhr.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822002580/0001683168-22-002580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822002580/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-002580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer